Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early prediction of pembrolizumab efficacy with PET/CT and liquid biopsy in untreated advanced NSCLC
jRCT1011200014Suspended
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC). Started Dec 2020; status: suspended.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1011200014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011200014.